中国药物应用与监测
中國藥物應用與鑑測
중국약물응용여감측
CHINESE JOURNAL OF DRUG APPLICATION AND MONITORING
2013年
4期
218-221
,共4页
降血糖药%用药金额%用药频度%日平均费用
降血糖藥%用藥金額%用藥頻度%日平均費用
강혈당약%용약금액%용약빈도%일평균비용
Hypoglycemic Drug%Consumption sum%DDDs%DDC
目的：了解我院降血糖药物以及基于胰高血糖素样肽-1（GLP-1）新型降糖药物的使用情况。方法：以计算机信息管理系统中药物的发出数量为依据，采用金额排序法和用药频度分析法，根据药物限定日剂量计算DDDs及日平均费用（DDC），并进行排序。结果：2008–2012年，我院降血糖药的销售金额持续快速增长。胰岛素及胰岛素类似物与α-葡萄糖苷酶抑制剂的销售金额相当，连续5年位居前两位，所占份额均已上升至30%以上。5年来，阿卡波糖的DDDs增长了1倍，连续处于首位。二甲双胍的DDDs从2009年的第3位上升至2012年的第2位，增长1.86倍，DDC却始终位于后3位（由6.48元降至5.84元）。结论：2008–2012年，我院降糖药的需求量逐年增加，药物种类较全面，引进了新型降糖药物。
目的：瞭解我院降血糖藥物以及基于胰高血糖素樣肽-1（GLP-1）新型降糖藥物的使用情況。方法：以計算機信息管理繫統中藥物的髮齣數量為依據，採用金額排序法和用藥頻度分析法，根據藥物限定日劑量計算DDDs及日平均費用（DDC），併進行排序。結果：2008–2012年，我院降血糖藥的銷售金額持續快速增長。胰島素及胰島素類似物與α-葡萄糖苷酶抑製劑的銷售金額相噹，連續5年位居前兩位，所佔份額均已上升至30%以上。5年來，阿卡波糖的DDDs增長瞭1倍，連續處于首位。二甲雙胍的DDDs從2009年的第3位上升至2012年的第2位，增長1.86倍，DDC卻始終位于後3位（由6.48元降至5.84元）。結論：2008–2012年，我院降糖藥的需求量逐年增加，藥物種類較全麵，引進瞭新型降糖藥物。
목적：료해아원강혈당약물이급기우이고혈당소양태-1（GLP-1）신형강당약물적사용정황。방법：이계산궤신식관리계통중약물적발출수량위의거，채용금액배서법화용약빈도분석법，근거약물한정일제량계산DDDs급일평균비용（DDC），병진행배서。결과：2008–2012년，아원강혈당약적소수금액지속쾌속증장。이도소급이도소유사물여α-포도당감매억제제적소수금액상당，련속5년위거전량위，소점빈액균이상승지30%이상。5년래，아잡파당적DDDs증장료1배，련속처우수위。이갑쌍고적DDDs종2009년적제3위상승지2012년적제2위，증장1.86배，DDC각시종위우후3위（유6.48원강지5.84원）。결론：2008–2012년，아원강당약적수구량축년증가，약물충류교전면，인진료신형강당약물。
Objective:To understand the application of hypoglycemic drugs and the new glucagon-like peptide 1 (GLP-1) in our hospital. Methods:Analysis was based on data of the amount of delivered drugs during 2008 to 2012 documented in hospital information system. Consumption sum ranking and frequency analysis methods were performed. DDDs and defined daily cost (DDC) were calculated and ranked according to defined daily dose (DDD). Results:The consumption sum of hypolycemic agents in our hospital increased rapidly and continuously.Consumption sum of insulins including its analogues andα-glucosidase inhibitors was similar with increasing shares to 30%, respectively, was in top two positions for five years. DDDs of acarbose increased by twice and was in the first place continuously, while DDDs of metformin (glucophage) rose to the second in 2012 from the third place in 2009 with an increasing of 1.86 times. In addition, DDC of metformin was always in the last three places and decreased from 6.48 yuan in 2008 to 5.84 yuan in 2012. GLP-1 receptor agonist exenatide was introduced into our hospital in 2012. Conclusion:Demand of hypolycemic agents increased year by year in our hospital. There were various categories of hypolycemic agents. The new type drug was available.
